Parameter
| Biomarker | BCR-ABL (p210) fusion gene (13a2/e14a2 subtype) | Full name | Breakpoint Cluster Region - Abelson murine leukemia viral oncogene homolog 1 (p210) fusion gene (13a2/e14a2 subtype) | Molecular Type | Nucleic acid (fusion gene) |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis, subtype differentiation |
| Disease | Chronic Myeloid Leukemia(CML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Leukemic cell/patient sample (nanocluster beacon fluorescence technology) | ||
| Pathobiological Mechanisms | The chromosomal translocation t(9;22) is the cause, with significant differences in clinical manifestations, treatment efficacy, and prognosis between the two subtypes. | ||||
| Clinical Availability Status | Technical validation: Subtype identification can be completed within 40 minutes, with detection limits of 16pM (e13a2) and 9pM (e14a2), respectively. | ||||
| Notes and Dynamics | Achieve high-efficiency single-tube detection to provide subtype-based evidence for precision therapy. | ||||